BR112020003829A2 - método para facilitar a saída de urina a partir do rim, cateter ureteral e sistema para induzir pressão negativa em uma porção do trato urinário de um paciente - Google Patents
método para facilitar a saída de urina a partir do rim, cateter ureteral e sistema para induzir pressão negativa em uma porção do trato urinário de um paciente Download PDFInfo
- Publication number
- BR112020003829A2 BR112020003829A2 BR112020003829-6A BR112020003829A BR112020003829A2 BR 112020003829 A2 BR112020003829 A2 BR 112020003829A2 BR 112020003829 A BR112020003829 A BR 112020003829A BR 112020003829 A2 BR112020003829 A2 BR 112020003829A2
- Authority
- BR
- Brazil
- Prior art keywords
- side wall
- diameter
- funnel support
- drainage lumen
- coil
- Prior art date
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 227
- 210000003734 kidney Anatomy 0.000 title claims abstract description 222
- 238000000034 method Methods 0.000 title claims abstract description 141
- 210000001635 urinary tract Anatomy 0.000 title claims description 35
- 210000000626 ureter Anatomy 0.000 claims abstract description 159
- 210000000244 kidney pelvis Anatomy 0.000 claims abstract description 130
- 238000003780 insertion Methods 0.000 claims abstract description 22
- 230000037431 insertion Effects 0.000 claims abstract description 22
- 239000012530 fluid Substances 0.000 claims description 250
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 22
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 22
- 238000004891 communication Methods 0.000 claims description 20
- 239000011148 porous material Substances 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000002513 implantation Methods 0.000 claims description 12
- 239000004816 latex Substances 0.000 claims description 11
- 229920000126 latex Polymers 0.000 claims description 11
- 229920001296 polysiloxane Polymers 0.000 claims description 11
- -1 polytetrafluoroethylene Polymers 0.000 claims description 11
- 229920002635 polyurethane Polymers 0.000 claims description 10
- 239000004814 polyurethane Substances 0.000 claims description 10
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 10
- 239000004800 polyvinyl chloride Substances 0.000 claims description 10
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 9
- 239000004332 silver Substances 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 8
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 8
- 239000010931 gold Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000010935 stainless steel Substances 0.000 claims description 8
- 229910001220 stainless steel Inorganic materials 0.000 claims description 8
- 239000010936 titanium Substances 0.000 claims description 8
- 229910052719 titanium Inorganic materials 0.000 claims description 8
- 230000008093 supporting effect Effects 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 229910001316 Ag alloy Inorganic materials 0.000 claims description 4
- 229910001020 Au alloy Inorganic materials 0.000 claims description 4
- 229910000881 Cu alloy Inorganic materials 0.000 claims description 4
- 229910000990 Ni alloy Inorganic materials 0.000 claims description 4
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 23
- 210000003932 urinary bladder Anatomy 0.000 description 197
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 108
- 230000014759 maintenance of location Effects 0.000 description 106
- 229940109239 creatinine Drugs 0.000 description 54
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 34
- 210000003708 urethra Anatomy 0.000 description 34
- 239000000463 material Substances 0.000 description 33
- 210000005239 tubule Anatomy 0.000 description 30
- 238000011282 treatment Methods 0.000 description 28
- 238000009826 distribution Methods 0.000 description 27
- 238000005534 hematocrit Methods 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 208000009304 Acute Kidney Injury Diseases 0.000 description 20
- 206010020565 Hyperaemia Diseases 0.000 description 20
- 208000033626 Renal failure acute Diseases 0.000 description 20
- 201000011040 acute kidney failure Diseases 0.000 description 20
- 230000009724 venous congestion Effects 0.000 description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 19
- 230000009467 reduction Effects 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- 229910052708 sodium Inorganic materials 0.000 description 19
- 230000007423 decrease Effects 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 16
- 210000000885 nephron Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 210000001631 vena cava inferior Anatomy 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 230000005484 gravity Effects 0.000 description 15
- 230000002485 urinary effect Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- 238000012544 monitoring process Methods 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241000282887 Suidae Species 0.000 description 13
- 238000002637 fluid replacement therapy Methods 0.000 description 13
- 210000001736 capillary Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 11
- 230000003907 kidney function Effects 0.000 description 11
- 206010059484 Haemodilution Diseases 0.000 description 10
- 210000004276 hyalin Anatomy 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000012491 analyte Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002706 hydrostatic effect Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 8
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 8
- 102000013519 Lipocalin-2 Human genes 0.000 description 8
- 108010051335 Lipocalin-2 Proteins 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- 238000004873 anchoring Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000005084 renal tissue Anatomy 0.000 description 8
- 229910052710 silicon Inorganic materials 0.000 description 8
- 239000010703 silicon Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 206010016803 Fluid overload Diseases 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 7
- 210000002565 arteriole Anatomy 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000009103 reabsorption Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010016807 Fluid retention Diseases 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000009056 active transport Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- 229960001802 phenylephrine Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000002796 renal vein Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000210 loop of henle Anatomy 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000310247 Amyna axis Species 0.000 description 2
- 102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 2
- 101710182628 DNA fragmentation factor subunit alpha Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002665 bowman capsule Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000010024 tubular injury Effects 0.000 description 2
- 208000037978 tubular injury Diseases 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 240000002132 Beaucarnea recurvata Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000013156 embolectomy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000001282 glomerular podocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000003246 kidney medulla Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000008663 renal system process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000004148 unit process Methods 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/008—Implant devices for drainage of body fluids from one part of the body to another pre-shaped, for use in the urethral or ureteral tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0074—Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/008—Strength or flexibility characteristics of the catheter tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/048—Ureters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/73—Suction drainage systems comprising sensors or indicators for physical values
- A61M1/732—Visual indicating means for vacuum pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/78—Means for preventing overflow or contamination of the pumping systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
- A61M1/87—Details of the aspiration tip, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1082—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1085—Bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1089—Urethra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- External Artificial Organs (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/687,064 US10765834B2 (en) | 2015-07-20 | 2017-08-25 | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
| US15/687,064 | 2017-08-25 | ||
| PCT/IB2018/056462 WO2019038734A1 (en) | 2017-08-25 | 2018-08-24 | URBER AND VESICAL PROBES AND METHODS OF INDUCING NEGATIVE PRESSURE TO INCREASE RENAL INFUSION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020003829A2 true BR112020003829A2 (pt) | 2020-09-08 |
Family
ID=63638193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020003829-6A BR112020003829A2 (pt) | 2017-08-25 | 2018-08-24 | método para facilitar a saída de urina a partir do rim, cateter ureteral e sistema para induzir pressão negativa em uma porção do trato urinário de um paciente |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3672678A1 (https=) |
| JP (1) | JP2020531149A (https=) |
| CN (1) | CN111278498A (https=) |
| BR (1) | BR112020003829A2 (https=) |
| CA (1) | CA3073907A1 (https=) |
| MX (1) | MX2020002065A (https=) |
| WO (1) | WO2019038734A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348673B (es) | 2008-05-01 | 2017-06-23 | Convatec Tech Inc * | Dispositivo de drenaje rectal. |
| CN108578044A (zh) | 2011-03-17 | 2018-09-28 | 康沃特克科技公司 | 高阻隔性弹性体粪便导管或造口袋 |
| BR112016002257A2 (pt) | 2013-08-01 | 2017-12-12 | Convatec Technologies Inc | conector de saco de fechamento automático |
| GB201721956D0 (en) | 2017-12-27 | 2018-02-07 | Convatec Ltd | Female catheter locator tip |
| GB201721955D0 (en) | 2017-12-27 | 2018-02-07 | Convatec Ltd | Catheter wetting devices |
| CN109953776B (zh) * | 2019-04-09 | 2023-11-17 | 江南大学 | 肾盂尿液微生态采集仪 |
| WO2020251979A1 (en) | 2019-06-11 | 2020-12-17 | Convatec Technologies Inc. | Urine collection bags for use with catheter products, kits incorporating the same, and methods therefor |
| CN113908411A (zh) * | 2021-10-20 | 2022-01-11 | 武汉威润八方医疗科技有限公司 | 一种集成式输尿管支架管 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599291A (en) * | 1993-01-04 | 1997-02-04 | Menlo Care, Inc. | Softening expanding ureteral stent |
| US6500158B1 (en) * | 1997-03-26 | 2002-12-31 | The Trustees Of Columbia University In The City Of New York | Method of inducing negative pressure in the urinary collecting system and apparatus therefor |
| US6620202B2 (en) * | 2001-10-16 | 2003-09-16 | Scimed Life Systems, Inc. | Medical stent with variable coil and related methods |
| US20050137614A1 (en) * | 2003-10-08 | 2005-06-23 | Porter Christopher H. | System and method for connecting implanted conduits |
| DK1957130T3 (da) | 2005-12-09 | 2010-11-22 | Dsm Ip Assets Bv | Hydrofilt overtræk omfattende en polyelektrolyt |
| US10512713B2 (en) * | 2015-07-20 | 2019-12-24 | Strataca Systems Limited | Method of removing excess fluid from a patient with hemodilution |
-
2018
- 2018-08-24 BR BR112020003829-6A patent/BR112020003829A2/pt not_active Application Discontinuation
- 2018-08-24 WO PCT/IB2018/056462 patent/WO2019038734A1/en not_active Ceased
- 2018-08-24 CN CN201880069239.0A patent/CN111278498A/zh active Pending
- 2018-08-24 MX MX2020002065A patent/MX2020002065A/es unknown
- 2018-08-24 EP EP18772908.2A patent/EP3672678A1/en not_active Withdrawn
- 2018-08-24 CA CA3073907A patent/CA3073907A1/en active Pending
- 2018-08-24 JP JP2020511298A patent/JP2020531149A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019038734A1 (en) | 2019-02-28 |
| CA3073907A1 (en) | 2019-02-28 |
| CN111278498A (zh) | 2020-06-12 |
| EP3672678A1 (en) | 2020-07-01 |
| MX2020002065A (es) | 2020-10-16 |
| JP2020531149A (ja) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12357793B2 (en) | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion | |
| US20220265914A1 (en) | Negative Pressure Therapy System | |
| US12076225B2 (en) | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function | |
| US10765834B2 (en) | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion | |
| EP3614963B1 (en) | Catheter device and method for inducing negative pressure in a patient's bladder | |
| US12274832B2 (en) | Percutaneous urinary catheter | |
| EP3672656B1 (en) | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion | |
| EP3570750B1 (en) | System for removing excess fluid from a patient with hemodilution | |
| BR112020003829A2 (pt) | método para facilitar a saída de urina a partir do rim, cateter ureteral e sistema para induzir pressão negativa em uma porção do trato urinário de um paciente | |
| BR112021010025A2 (pt) | cateter, sistema para induzir pressão negativa em uma porção de um trato urinário de um paciente e método para remover fluido de um trato urinário de um paciente | |
| TW202034863A (zh) | 用於誘發負壓以增加腎功能的輸尿管導管、膀胱導管、系統、套件、及方法 | |
| US20210046278A1 (en) | Catheter Device and Method for Inducing Negative Pressure in a Patient's Bladder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ROIVIOS LIMITED (BS) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |